Application of the dermatology life quality index in clinical trials of biologics for psoriasis

Chinese Journal of Integrative Medicine

Volumn 18, Issue 3, 2012, Pages 179-185

  Basra, Mohammad Khurshid Azam ^a   Hussain, Sadath ^a  

^a CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

Biologics; Dermatology Life Quality Index; Psoriasis; Quality of life

Indexed keywords

ADALIMUMAB; ALEFACEPT; BIOLOGICAL FACTOR; ETANERCEPT; INFLIXIMAB; USTEKINUMAB;

ARTICLE; CLINICAL TRIAL (TOPIC); DERMATOLOGY QUALITY OF LIFE INDEX; DISEASE SEVERITY; DRUG EFFICACY; HUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSORIASIS; QUALITY OF LIFE; QUALITY OF LIFE INDEX; TREATMENT DURATION;

BIOLOGICAL AGENTS; CLINICAL TRIALS AS TOPIC; DERMATOLOGIC AGENTS; DERMATOLOGY; HUMANS; PSORIASIS; QUALITY OF LIFE;

EID: 84862738205     PISSN: 16720415     EISSN: 19930402     Source Type: Journal    
DOI: 10.1007/s11655-012-1007-0     Document Type: Article

References (50)

1. Najarian DJ, Gottlieb AB. Connections between psoriasis and Crohn's disease. J Am Acad Dermatol 2003;48:805-821. (Pubitemid 36706210)
2. Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. JAMA 2006;296:1735-1741. (Pubitemid 44547793)
3. Gisondi P, Tessari G, Conti A, Piaserico S, Schianchi S, Peserico A, et al. Prevalence of metabolic syndrome in patients with psoriasis: a hospital based case-control study. Br J Dermatol 2007;157:68-73. (Pubitemid 46934281)
4. Gelfand JM, Berlin J, van Voorhees A, Margolis DJ. Lymphoma rates are low but increased in patients with psoriasis: results from a population-based cohort study in the United Kingdom. Arch Dermatol 2003;139:1425-1429. (Pubitemid 37433132)
5. Esposito M, Saraceno R, Giunta A, Maccarone M, Chimenti S. An Italian study on psoriasis and depression. Dermatology 2007;212:123-127. (Pubitemid 43260727)
6. Menter A, Gottlieb A, Feldman SR, Van Voorhees AS, Leonardi CL, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 2008;58:826-850. (Pubitemid 351509656)
7. Langley R, Krueger G, Griffiths C. Psoriasis: epidemiology, clinical features, and quality of life. Ann Rheum Dis 2005;64(Suppl 2):ii18.
8. Johnson M, Roberts J. Skin conditions and related need for medical care among persons 1-74 years. United States, 1971-1974. Vital and Health Statistics. Series 11, Data from the National Health Survey 1978(212):i.
9. Rea J, Newhouse ML, Halil T. Skin disease in Lambeth. A community study of prevalence and use of medical care. Br J Prev Soc Med 1976;30:107-114.
10. Lin XR. Psoriasis in China. J Dermatol 1993;20:746-755.
11. Finlay AY, Coles E. The effect of severe psoriasis on the quality of life of 369 patients. Br J Dermatol 1995;132:236-244.
12. Krueger G, Koo J, Lebwohl M, Menter A, Stern RS, Rolstad T. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol 2001;137:280-284. (Pubitemid 32240779)
13. Rapp SR, Feldman SR, Exum ML, Fleischer Jr AB, Reboussin DM. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999;41:401-407. (Pubitemid 29418506)
14. Bronsard V, Paul C, Prey S, Puzenat E, Gourraud P. What are the best outcome measures for assessing quality of life in plaque type psoriasis? A systematic review of the literature. J Eur Acad Dermatol Venereol 2010;24:17-22.
15. Eghlileb A, Davies E, Finlay AY. Psoriasis has a major secondary impact on the lives of family members and partners. Br J Dermatol 2007;156:1245-1250. (Pubitemid 47029819)
16. Ramsay B, O'Reagan M. A survey of the social and psychological effects of psoriasis. Br J Dermatol 1988;118:195-201.
17. De Arruda L, De Moraes A. The impact of psoriasis on quality of life. Br J Dermatol 2001;144:33-36.
18. Kirby B, Richards HL, Woo P, Hindle E, Main CJ, Griffiths CEM. Physical and psychologic measures are necessary to assess overall psoriasis severity. J Am Acad Dermatol 2001;45:72-76. (Pubitemid 32655696)
19. Le Cleach L, Chassany O, Levy A, Wolkenstein P, Chosidow O. Poor reporting of quality of life outcomes in dermatology randomized controlled clinical trials. Dermatology 2007;216:46-55.
20. Finlay AY, Khan G. Dermatology Life Quality Index (DLQI) - a simple practical measure for routine clinical use. Clin Exp Dermatol 1994;19:210-216. (Pubitemid 24194579)
21. Basra MKA, Fenech R, Gatt R, Salek M, Finlay A. The Dermatology Life Quality Index 1994-2007: a comprehensive review of validation data and clinical results. Br J Dermatol 2008;159:997-1035.
22. www.dermatology.org.uk. Accessed on December 18, 2011.
23. Hongbo Y, Thomas CL, Harrison MA, Salek MS, Finlay AY. Translating the science of quality of life into practice: what do Dermatology Life Quality Index Scores mean? J Invest Dermatol 2005;125:659-664.
24. Khilji F, Gonzalez M, Finlay A. Clinical meaning of change in Dermatology Life Quality Index scores. Br J Dermatol 2002;147(suppl 62):50.
25. Goffe B, Cather JC. Etanercept: an overview. J Am Acad Dermatol 2003;49 (Suppl):105-111.
26. Feldman SR, Kimball AB, Krueger GG, Woolley JM, Lalla D, Jahreis A. Etanercept improves the health-related quality of life of patients with psoriasis: results of a phase III randomized clinical trial. J Am Acad Dermatol 2005;53:887-889. (Pubitemid 41501389)
27. Gottlieb AB, Matheson RT, Lowe N, Krueger GG, Kang S, Goffe BS, et al. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol 2003;139:1627-1632. (Pubitemid 37523083)
28. Krueger GG, Langley R, Finlay AY, Griffiths C, Woolley J, Lalla D, et al. Patient reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial. Br J Dermatol 2005;153:1192-1199. (Pubitemid 41779576)
29. Tyring S, Gordon KB, Poulin Y, Langley RG, Gottlieb AB, Dunn M, et al. Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis. Arch Dermatol 2007;143:719-726. (Pubitemid 46955730)
30. Tyring S, Gottlieb A, Papp K, Gordon K, Leonardi C, Wang A, et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet 2006;367:29-35. (Pubitemid 43038667)
31. Weinberg JM. An overview of infliximab, etanercept, efalizumab, and alefacept as biologic therapy for psoriasis. Clin Ther 2003;25:2487-2505. (Pubitemid 37373927)
32. Menter A, Feldman SR, Weinstein GD, Papp K, Evans R, Guzzo C, et al. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol 2007;56:31.e1-e31. e15.
33. Chaudhari U, Romano P, Mulcahy L, Dooley L, Baker D, Gottlieb A. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 2001;357:1842-1847. (Pubitemid 32539117)
34. Gottlieb AB, Evans R, Li S, Dooley LT, Guzzo CA, Baker D, et al. Infliximab induction therapy for patients with severe plaquetype psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 2004;51:534-542. (Pubitemid 39278071)
35. Reich K, Nestle FO, Papp K, Ortonne JP, Evans R, Guzzo C, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, doubleblind trial. Lancet 2005;366:1367-1374. (Pubitemid 41443403)
36. Reich K, Nestle FO, Wu Y, Bala M, Eisenberg D, Guzzo C, et al. Infliximab treatment improves productivity among patients with moderate-to-severe psoriasis. Eur J Dermatol 2007;17:381-386. (Pubitemid 47425903)
37. Ellis CN, Krueger GG. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med 2001;345:248-255. (Pubitemid 32695064)
38. Gordon KB, Vaishnaw AK, O'Gorman J, Haney J, Menter A. Treatment of psoriasis with alefacept: correlation of clinical improvement with reductions of memory T-cell counts. Arch Dermatol 2003;139:1563-1570. (Pubitemid 37523074)
39. Feldman S, Menter A, Koo J. Improved health related quality of life following a randomized controlled trial of alefacept treatment in patients with chronic plaque psoriasis. Br J Dermatol 2004;150:317-326. (Pubitemid 38352471)
40. Finlay AY, Salek MS, Haney J. Intramuscular alefacept improves health-related quality of life in patients with chronic plaque psoriasis. Dermatology 2000;206:307-315.
41. Ellis CN, Mordin MM, Adler EY. Effects of alefacept on healthrelated quality of life in patients with psoriasis: results from a randomized, placebo-controlled phase III trial. Am J Clin Dermatol 2003;4:131-139. (Pubitemid 36259520)
42. Ortonne JP, Prinz JC. Alefacept: a novel and selective biologic agent for the treatment of chronic plaque psoriasis. Eur J Dermatol 2004;14:41-45. (Pubitemid 38187097)
43. Gordon KB, Langley RG, Leonardi C, Toth D, Menter MA, Kang S, et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol 2006;55:598-606. (Pubitemid 44436647)
44. Papoutsaki M, Chimenti MS, Costanzo A, Talamonti M, Zangrilli A, Giunta A, et al. Adalimumab for severe psoriasis and psoriatic arthritis: an open-label study in 30 patients previously treated with other biologics. J Am Acad Dermatol 2007;57:269-275. (Pubitemid 47048857)
45. Gladman D, Mease P, Cifaldi M, Perdok R, Sasso E, Medich J. Adalimumab improves joint-related and skin-related functional impairment in patients with psoriatic arthritis: patient-reported outcomes of the Adalimumab Effectiveness in Psoriatic Arthritis Trial. Ann Rheum Dis 2007;66:163-168. (Pubitemid 46226048)
46. Asahina A, Nakagawa H, Etoh T, Ohtsuki M. Adalimumab in Japanese patients with moderate to severe chronic plaque psoriasis: efficacy and safety results from a phase II/III randomized controlled study. J Dermatol 2010;37:299-310.
47. Leonardi CL, Kimball AB, Papp KA, Yeilding N, Guzzo C, Wang Y, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, doubleblind, placebo-controlled trial (PHOENIX 1). Lancet 2008;371:1665-1674. (Pubitemid 351671883)
48. Papp KA, Langley RG, Lebwohl M, Krueger GG, Szapary P, Yeilding N, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, doubleblind, placebo-controlled trial (PHOENIX 2). Lancet 2008;371:1675-1684. (Pubitemid 351671884)
49. Krueger GG, Langley RG, Leonardi C, Yeilding N, Guzzo C, Wang Y, et al. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med 2007;356:580-592. (Pubitemid 46220818)
50. Smith CH, Anstey A, Barker J, Burden A, Chalmers R, Chandler D, et al. British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009. Br J Dermatol 2009;161:987-1019.